Stealth BioTherapeutics Corp (NASDAQ:MITO) Receives $24.83 Average Price Target from Brokerages

Shares of Stealth BioTherapeutics Corp (NASDAQ:MITO) have been assigned an average recommendation of “Buy” from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $24.83.

MITO has been the subject of a number of recent analyst reports. BMO Capital Markets initiated coverage on shares of Stealth BioTherapeutics in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $29.00 target price for the company. Evercore ISI initiated coverage on shares of Stealth BioTherapeutics in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $35.00 target price for the company. HC Wainwright initiated coverage on shares of Stealth BioTherapeutics in a research note on Tuesday. They issued a “buy” rating and a $30.00 target price for the company. Zacks Investment Research upgraded shares of Stealth BioTherapeutics from a “hold” rating to a “buy” rating and set a $16.00 target price for the company in a research note on Wednesday, May 15th. Finally, Nomura initiated coverage on shares of Stealth BioTherapeutics in a research note on Tuesday, March 12th. They issued a “buy” rating and a $23.00 target price for the company.

An institutional investor recently bought a new position in Stealth BioTherapeutics stock. Dean Capital Investments Management LLC acquired a new stake in shares of Stealth BioTherapeutics Corp (NASDAQ:MITO) in the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 50,420 shares of the company’s stock, valued at approximately $646,000. Dean Capital Investments Management LLC owned 0.18% of Stealth BioTherapeutics at the end of the most recent quarter. 1.09% of the stock is owned by institutional investors.

Shares of Stealth BioTherapeutics stock opened at $13.30 on Tuesday. Stealth BioTherapeutics has a 52-week low of $11.11 and a 52-week high of $20.99. The company has a market capitalization of $371.60 million and a PE ratio of -9.43.

Stealth BioTherapeutics (NASDAQ:MITO) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.14. As a group, research analysts forecast that Stealth BioTherapeutics will post -0.28 earnings per share for the current year.

Stealth BioTherapeutics Company Profile

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.

See Also: What is the Ex-Dividend Date in Investing?

Analyst Recommendations for Stealth BioTherapeutics (NASDAQ:MITO)

Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.